Mark Ford is an antitrust litigator and counselor. He represents clients across a variety of industries, and has extensive experience defending antitrust class actions and litigating cases at the intersection of antitrust and intellectual property law.
For clients in the life sciences industry, Mr. Ford has litigated matters, and regularly counsels clients, concerning brand-generic settlements as well as defending allegations of sham litigation, Walker Process fraud, improper “Orange Book” listings, and “product hopping.” He regularly advises clients on the antitrust implications of life cycle management strategies. He has represented pharmaceutical companies and their employees in federal court, before the Federal Trade Commission, and in responding to inquiries from the European Commission.
Mr. Ford also has extensive experience litigating matters and advising clients on competition issues arising from the assertion of standard-essential patents (SEPs). He has litigated several SEP antitrust claims in federal courts on behalf of clients alleging that SEP holders have violated commitments to license SEPs on fair, reasonable and non-discriminatory terms. Mr. Ford has also appeared before the Department of Justice to address issues of SEP abuse.
Finally, Mr. Ford has represented clients from a variety of industries in federal courts and in agency investigations in matters concerning alleged monopolization, price fixing and horizontal mergers. In particular, he defends clients in follow-on civil litigation arising from cartel enforcement matters, including direct and indirect purchaser class actions.